Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: Analysis of administrative health databases in Québec, Canada

Drugs and Aging

Volumn 25, Issue 10, 2008, Pages 879-884

  Bernatsky, Sasha ^a,c   Ehrmann Feldman, Debbie ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Elderly; Methotrexate, therapeutic use; Rheumatoid arthritis, treatment

Indexed keywords

FOLIC ACID; METHOTREXATE;

AGED; AGING; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CHRONIC DISEASE; DATABASES, FACTUAL; FEMALE; HEALTH SERVICES FOR THE AGED; HUMANS; MALE; MEDICATION ADHERENCE; METHOTREXATE; POPULATION SURVEILLANCE; QUEBEC; RURAL POPULATION; TREATMENT OUTCOME; URBAN POPULATION;

EID: 52449099194     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825100-00007     Document Type: Article

References (21)

1. Hartzheim LA, Goss GL. Rheumatoid arthritis: a case study. Nurs Clin North Am 1998; 33 (4): 595-602
2. Pincus T, Sokka T. How can the risk of long-term consequences of rheumatoid arthritis be reduced? Best Pract Res Clin Rheumatol 2001; 15 (1): 139-70
3. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford) 2007; 46 (7): 1157-60
4. Potter T, Mulherin D, Pugh M, et al. Early intervention with disease-modifying therapy for rheumatoid arthritis: where do the delays occur? Rheumatology 2002; 41 (8): 953-5
5. Emery P, Breedveld FC, Dougados M, et al. Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis 2002; 61 (4): 290-7
6. Irvine S, Munro R, Porter D. Early referral, diagnosis, and treatment of rheumatoid arthritis: evidence for changing medical practice. Ann Rheum Dis 1999; 58 (8): 510-3
7. McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol 1993; 20 (11): 1850-6
8. Tett SE, Triggs EJ. Use of methotrexate in older patients: a risk-benefit assessment. Drugs Aging 1996; 9 (6): 458-71
9. Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17 (8): 994-1002
10. Kaipiainen-Seppanen O, Aho K, Isomaki H, et al. Shift in the incidence of rheumatoid arthritis toward elderly patients in Finland during 1975-1990. Clin Exp Rheumatol 1996; 14 (5): 537-42
11. Savolainen E, Kaipiainen-Seppanen O, Kroger L, et al. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 2003; 30 (11): 2460-8
12. Tutuncu Z, Reed G, Kremer J, et al. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis 2006; 65 (9): 1226-9
13. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-83
14. Treharne GJ, Lyons AC, Hale ED, et al. 'Compliance' is futile but is 'concordance' between rheumatology patients and health professionals attainable? Rheumatology (Oxford) 2006; 45 (1): 1-5
15. Garber MC, Nau DP, Erickson SR, et al. The concordance of self-report with other measures of medication adherence: a summary of the literature. Med Care 2004; 42 (7): 649-52
16. Mulherin D, Wong M. Drug survival in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45 (9): 1178-9
17. Wolfe F. The epidemiology of drug treatment failure in rheumatoid arthritis. Baillieres Clin Rheumatol 1995; 9 (4): 619-32
18. Pincus T, Marcum SB, Callahan LF. Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19 (12): 1885-94
19. Yazici Y, Sokka T, Kautiainen H, et al. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64 (2): 207-11
20. Ortendahl M, Schettler JD, Fries JF. Factors influencing length of time taking methotrexate in rheumatoid arthritis. J Rheumatol 2000; 27 (5): 1139-47
21. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. J Rheumatol 2006; 33 (2): 248-55